期刊文献+

CpGDNA预防小鼠哮喘模型的形成 被引量:10

An Experimental Study of the Prevention of CpG DNA on the Production of a Murine Asthmatic Model
下载PDF
导出
摘要 目的 研究含胞嘧啶鸟嘌呤核苷酸的免疫刺激元件 (CpGDNA)能否预防卵蛋白致敏小鼠哮喘模型的形成。方法 将 18只BALB/c小鼠均分为 3组 ,其中卵蛋白致敏哮喘组 (OVA组 )和CpG预防组 (CpG组 )皮下注射卵蛋白致敏制作哮喘模型 ,然后用卵蛋白激发 2次 ;阴性对照组 (NS组 )皮下注射生理盐水 ,然后生理盐水激发 2次。CpG组在致敏前腹腔注射CpGDNA 10 0 μg/ 10 0 μL ,其他两组不作干预。 3组分别在第 2次激发后 2 4h测外周血OVA特异性IgE、IgG1、IgG2a,并处死小鼠测肺泡灌洗液 (BALF)中的细胞总数及嗜酸性粒细胞 (EOS)计数 ,肺组织病理切片观察形态学改变 ,并测定脾细胞培养上清液中OVA特异性IFN γ。结果 CpG组BALF中细胞总数和嗜酸性粒细胞明显低于OVA组 ,P <0 .0 5 ;CpG组肺组织炎症反应较OVA组明显减轻 ;CpG组脾细胞培养上清液中OVA特异性IFN γ的浓度明显高于OVA组 ,P <0 .0 5 ;CpG组外周血OVA特异性IgE和IgG1均低于OVA组 ,P <0 .0 5 ;CpG组IgG2a较OVA组为高 ,P <0 .0 5。 Purpose. To investigate the prevention of CpG DNA on the production of a murine asthmatic model. Methods. 18 Female BALB/c mice were divided into 3 groups. Group CpG and group ovalbumin(OVA) were sensitized subcutaneouly with OVA/alum and challenged with OVA. Group NS were injected and challenged with NS. Group CpG was injected CpG DNA 100 g/100 μL intraperitioneally prior to sensitization. Blood samples, bronchoalveolar lavage fluid(BALF), lung tissues and spleen cells were collected one day after challenge. Serum OVA-specific IgE, IgG1, IgG2a were measured by ELISA. Total cell numbers and classification of BALF were counted. IFN-γ producted by OVA-stimulated spleen cells was determined by ELISA. Results. Pathological examination showed that in group CpG airway inflammation and eosinophil infiltration in airway and lung parenchyma were inhibited as compared with group OVA. In group CpG total cell numbers and Eosinophilia of BALF were decreased, serum levels of IgE and IgG1 were decreased, serum level of IgG2a and the level of IFN-γ in spleen cell supernatants were increased as compared with group OVA. Conclusions. CpG DNA could prevent the production of a murine asthmatic model.
出处 《复旦学报(医学版)》 EI CAS CSCD 北大核心 2002年第5期376-378,共3页 Fudan University Journal of Medical Sciences
  • 相关文献

参考文献12

  • 1[1]Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA se quences necessary for effective intradermal gene immunization. Science, 1996,273 ( 19 ): 352
  • 2[2]Broide D, Schwarze J, Tighe H, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperres-ponsiveness in mice. J Immunol, 1998,161 (12) :7054
  • 3[3]Klinman DM. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 12 and interferon-γ. Proc Natl Acad Sci USA, 1996,93: 2879
  • 4[4]Kline JN, Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol, 1998,160(6) :2555
  • 5[5]Corry D, Folkesson HG, Warnock M, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med , 1996,183:109
  • 6[6]Walker C,Bode E,Boer L, et al. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokines production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis, 1992,146:109
  • 7[7]Drazen JM, Ann JP, Austen KF, et al. Sorting out the cytokines of asthma. J Exp Med, 1996,183:1
  • 8[8]Broide D, Raz E. DNA-based immunization for asthma. Imt Arch Allergy lmmunol , 1999,118: 453
  • 9[9]Spiegelberg HL,Tighe H, Roman M, et al. Inhibition of IgE formation and allergic inflammation by allergen gene imxunization and by CpG motif immunostimulatory oligodeoxynucleotides. Allergy, 1998,53: 93
  • 10[10]Raz E,Tighe H, Sato Y, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA, 1996,93:5141

同被引文献109

  • 1肖建军,李孟荣.小鼠哮喘模型的气道高反应性检测[J].国外医学(儿科学分册),2005,32(6):323-326. 被引量:2
  • 2吕小华,吴铁,覃冬云.甘草对慢性小鼠哮喘模型气道炎症及外周血Th_1/Th_2失衡的影响[J].中国临床药理学与治疗学,2006,11(5):532-534. 被引量:20
  • 3Krieg A M, Yi A K, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation[J]. Nature, 1995, 374: 546-549.
  • 4Weqmann M. Th2 cells as targets for therapeutic intervention in allergic bronchial asthma[J]. Expert Rev Mol Diagn, 2009,9(1): 85-100.
  • 5Kline J N. Immunotherapy of asthma using CpG oligodeoxynucleotides[J]. Immunol Res, 2007,39(1-3):279-286.
  • 6Mousavi T, Salek Moghadam A, Falak R ,et al. Immunotherapy of Chenopodium album induced asthma by intranasal administration of CpG otigodeoxynucleotides in BALB/c mice[J]. Iran J Immunol, 2008,5(1 ):57-63.
  • 7Shirota H, Sano K, Kikuchi T, et al Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator[J]. J Immunol, 2000, 164: 5575-5582.
  • 8Hamelmann E, Schwarze J, Takeda K, et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography[J]. Am J Respir Crit Care Med, 1997, 156 (3):766-775.
  • 9Agrawal D K, Edwan J, Kandimalla E R, et al. Novel immunomodulatory oligonucle-otides prevent development of allergic airway inflammation and airway hyperre-sponsiveness in asthma[J]. Inter Immunopharmacol, 2004, 4(1): 127-138.
  • 10Senti G, Johansen P, Haug S , et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/lla clinical trial[J]. Clin Exp Allergy, 2009, 39(4):562-570.

引证文献10

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部